Who
Larry Todd Edwards
Chief Commercial Officer
Company insider
Files Form 4 as: Chief Commercial Officer, Oruka Therapeutics; SVP Chief Commercial Officer, Arcutis Biotherapeutics.
In numbers
- Trades disclosed
- 31
- Buys
- 1
- Sells
- 8
- Bought
- $7,771
- Sold
- $1.4M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 27 Sep 2023
- Last trade
- 24 Aug 2026
- Last filed
- 25 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 24 Aug 2026filed 25 Aug 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 24 Aug 2026filed 25 Aug 2026 | ORKA Oruka Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 24 Aug 2026filed 25 Aug 2026 | ORKA Oruka Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 24 Aug 2026filed 25 Aug 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $90K3,584 at $25.16 | filing |
| 2 Mar 2026filed 3 Mar 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $2,669103 at $25.91 | filing |
| 2 Mar 2026filed 3 Mar 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $90K3,584 at $25.16 | filing |
| 2 Mar 2026filed 3 Mar 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $2,669103 at $25.91 | filing |
| 27 Feb 2026filed 3 Mar 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 27 Feb 2026filed 3 Mar 2026 | ARQT Arcutis Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —77,000 at $0.00 | filing |
| 27 Feb 2026filed 3 Mar 2026 | ARQT Arcutis Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —77,000 at $0.00 | filing |
| 27 Feb 2026filed 3 Mar 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $52K2,052 at $25.50 | filing |
| 2 Feb 2026filed 4 Feb 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $52K2,052 at $25.50 | filing |
| 6 Nov 2025filed 10 Nov 2025 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $733K29,131 at $25.16 | filing |
| 2 Oct 2025filed 6 Oct 2025 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $84K4,207 at $19.99 | filing |
| 2 Oct 2025filed 6 Oct 2025 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $6,172297 at $20.78 | filing |
| 19 May 2025filed 20 May 2025 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $105K7,451 at $14.07 | filing |
| 28 Feb 2025filed 4 Mar 2025 | ARQT Arcutis Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —99,000 at $0.00 | filing |
| 28 Feb 2025filed 4 Mar 2025 | ARQT Arcutis Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —43,000 at $0.00 | filing |
News
Arcutis Biotherapeutics (ARQT) Gets New Rating Uprgades from 2 Analysts; Shares ClimbARQT · insidermonkey.com · 20 Oct 2026Financial Review: Arcutis Biotherapeutics (NASDAQ:ARQT) and Iterum Therapeutics (NASDAQ:ITRM)ARQT · themarketsdaily.com · 6 Oct 2026
0 headlines in the last 90 days name Larry Todd Edwards; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.